Professor Barry Buckland has a PhD in Biochemical Engineering from University College London, obtained in 1974. He joined the Merck Research Laboratories (MRL) in 1980 and built a world class Bioprocess R&D group. He has been the leader of process development of all biologically made product candidates within the MRL pipeline and manufacture of Clinical Supplies during the past 20 years. Products developed within this timeline include MEVACOR®, ZOCOR®, IVOMEC®, CANCIDAS®, RECOMBIVAX HB®, VAQTA®, VARIVAX®, COMVAX®., ROTATEQ® (Rotavirus vaccine), ZOSTAVAX® (shingles vaccine) and GARDASIL® (HPV vaccine).

External awards and appointments include being elected to the National Academy of Engineering in 1997 and Fellow of University College London in 1998. Awards include the Donald Medal, UK Institute of Chemical Engineering in 2002, Prix Galien award: Member of team to receive Vaccine Award for Gardasil® in 2007, Merck Board of Directors Award for leading process development for licensure of four new vaccines in 2007 and the Marvin Johnson award by ACS for lifetime contribution to Biotechnology in 2008. He has haired two International Conferences on Cell Culture (Cell Culture Engineering IV and Cell Culture Engineering V) and co-chaired the first three International Conferences on Metabolic Engineering. He also co-chaired the first two International Conferences on Vaccine Technology.

Barry is the author or co-author of over 70 papers, and has been Visiting Professor at University College London for past 15 years. In October 2008, he was named by AIChE as one of the "One Hundred Chemical Engineers of the Modern Era" (defined as from World War II to Present) as part of the AIChE Centennial Celebration in Philadelphia, USA and also awarded Marvin Johnson Award by ACS (American Chemical Society) for lifetime contribution to Biotechnology. He was awarded PHRMA Discoverer of the Year award in April 2009 for development of the Merck HPV vaccine (along with Eliav Barr and Kathrin Jansen).

From May 2009 he has been the CEO of BiologicB.

Back to VISION 2020